A “skinny label” is one way that a generic drug can be commercialized in the US when only a subset of the brand’s uses lose exclusivity. The recent Supreme Court decision in the Caraco case may put a spotlight on the opportunities for “skinny label” generics. The article found here describes some of the issues and possible policy implications that may be associated with an increased use of “skinny labels.”
Policy solutions to improve access to fertility treatment and optimise patient care: consensus from an expert forum
Infertility affects more than 17% of people of reproductive age globally, yet access to ART remains uneven and often out of reach.